Budget Impact Analysis of Regorafenib for The Treatment in Third and Fourth Lines of Metastasic Colorectal Cancer in Spain
Abstract
Authors
E González Flores R Vera García E Sabater Cabrera E Tirado Mercier M Granell Villalon